Last updated on November 2017

A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects with Type 2 Diabetes Mellitus


Brief description of study

A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects with Type 2 Diabetes Mellitus

Detailed Study Description

This study is to support the development of MK-1293, a proposed follow-on insulin glargine, using Lantus™ (insulin glargine, Sanofi-aventis Pharmaceuticals, Frankfurt, Germany) as the comparator medicinal product. This study will assess the safety and efficacy of MK-1293 compared to Lantus™.

Clinical Study Identifier: TX81488

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Baylor Scott & White Research ...

Baylor Scott & White Research Institute
Dallas, TX USA
  Connect »